1. Torres-Guerrero E, Romano Quintanilla-Cedillo M, Ruiz-Esmenjaud J. Leishmaniasis: a review. F1000Research 2017; 6: 750. 2. Baneth G, Yasur-Landau D, Gilad M, Nachum-Biala Y. Canine leishmaniosis caused by Leishmania major and Leishmania tropica: comparative findings and serology. Parasites & Vectors 2017;10(1):113. 3. Gannavaram S, Debrabant A. Programmed cell death in leishmania: biochemical evidence and role in parasite infectivity. Frontiers in Cellular and Infection Microbiology 2012; 2:95. 4. Chenik M, Lakhal S, Benkhalef N, Louzir H. Approaches for the identification of potential excreted/secreted proteins of Leishmania major parasites. Parasitology 2006;132:493-509. 5. Lippert DN, Dwyer DM, Li F, Olafson RW. Phosphoglycosylation of a secreted acid phosphatase from Leishmania donovani. Journal of Glycobiology 1999; 9: 627-36. 6. Han C, Yu J, Zhang Z, et all. Immunomodulatory effects of Trichinella spiralis excretory-secretory antigens on macrophages. Experimental Parasitology 2018. 7. Selkirk ME, Lazari O, Matthews JB. Functional genomics of nematode acetylcholine esterases. Parasitology 2005;131 Suppl:S3-18. 8. Smith DM, Simon JK, Baker JR. Applications of nanotechnology for immunology. Nature Reviews Immunology 2013; 13(8): 592-605. 9. Azadi A, Hamidi M, Rouini M-R. Methotrexate-loaded chitosan nanogels as ‘Trojan Horses’ for drugdelivery to brain. Preparation and in vitro/in vivo characterization, International Journal of Biological Macromolecules 2013; 523-530. 10. Rampinoa A, Borgognaa M, Blasi b P, and Bellicha B. Chitosan nanoparticles: Preparation, size evolution and stability. International Journal of Pharmaceutics 2013. 11. Bulmera C, Margaritisa A, and Xenocostasb A. Production and characterization of novel chitosan nanoparticles for controlled release of rHu-Erythropoietin. Biochemical Journal 2012;61-69. 12. Munawar A, Jaweria T, Kishor M. An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery. Pharmaceutics 2017; 9:53. 13. Grenha A. Chitosan nanoparticles: A survey of preparation methods. Journal of Drug Targeting 2012. 14. Wong W, Tan Z, Othman N, Mohamed Z, et all. Analysis of Entamoeba histolytica Excretory-Secretory Antigen and Identification of a New Potential Diagnostic Marker. Clinical and Vaccine Immunology 2011; 1913-1917. 15. E Sanin D, P Mountfor A. Sm16, a major component of Schistosoma mansoni cercarial excretory/secretory products, prevents macrophage classical activation and delays antigen processing. Journal of Biomedical Science 2014. 16. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro and nanoparticles in drug delivery. Journal of Controlled Release 2004;100:5–28. 17. Kamat V, Bodas D, Paknikar K. Chitosan nanoparticles synthesis caught in action using microdroplet reactions. Scientific Reports 2016. 18. Yongmei Xu, Yumin Du. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. International Journal of Pharmaceutics 2003;250: 215-226. 19. Ansari M, Ebrahimi Samani S, Seraj Z, Khajeh K, HosseinKhani S. . Optimization of chitosan nanoparticles synthesis. Modares Journal of Biotechnology 2013;4 (2):65-73 20. Tahamtan A, Charostad J, Hoseini Shokouh J, Barati M. An Overview of Different Types of Immune Stimulating Adjuvants and Their Application. Paramedical Sciences and Military Health 2016; 11 (3) :43-51. 21. Hariharan M, Varghese N, Cherian B, Sreenivasan PV, Paul J, Antony A. Synthesis and characterisation of Ca-Co3 (Calcite) Nano Particles from Cockle Shells using Chitosan as Precursor. International Journal of Scientific and Research Publication 2014;4(10):1-5. 22. Mehrani H, Mahmoodzadeh A. Immunological Effects of Leishmania major Secretory and Excretory products on cutaneous Leishmaniasis in BALB/C Mice. Molecular and Biochemical Parasitology 2007; 9-19. 23. Jalaj K. Gour. Identification of TH1-responsive leishmanial excretory – secretory antigens 2012: 355-361. 24. He P, Davis SS, Illum L. In-vitro evaluation of the muco-adhesive properties of chitosan microspheres. International Journal of Pharmaceutics 1998; 166: 75-88. 25. Bivas-Benita M, van Meijgaarden KE, Franken KL. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A0201-restricted T-cell epitopes of Mycobacterium Tuberculosis. Vaccine 2004; 22(13–14): 1609 1615. 26. Tebianian M. Production of a mycobacterium tuberculosis fusion protein consist of ESAT-6 with HSP70 and evaluation of immune responses following intranasal administration. PhD Thesis. Tarbiat Modares University. 2009; 1-131. 27. Danesh-bahreini MA, SHokri J, Samiei A, Kamali-Sarvestani E, Barzegar-jalali M, Mohammadi-samani S. Nanovaccine for leishmaniasis: preparation of chirosan nanoparticles containing leishmanial superoxide dismutase and evaluation of its immunogenicity in BALB/C mice. International Kournal of Nanomedicine 2011:6 835-842. 28. Rampino A, Borgogna M, Blasi P, et al. Chitosan nanoparticles: Preparation, size evolution and stability. International Journal of Pharmaceutics 2013;455:219– 228. 29. Xue M, Hu S, Lu Y, et al. Development of chitosan nanoparticles as drug delivery system for a prototype capsid inhibitor. International Journal of Pharmaceutics 2015;495:771-782. 30. Sharma A, Kumar U, Madan J, et al. Soluble telmisartan bearing poly (ethylene glycol) conjugated chitosan nanoparticles augmented drug delivery, cytotoxicity, apoptosis and cellular uptake in human cervical cancer cells. Materials Science and Engineering 2017;72:69-76. 31. Xaus J, Comalada M, Lloberas J, et all. LPS induces apoptosis in macrophages mostly through the autocrine production of TNF-α. Blood 2000; 95:3823-3831.